Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Sun Pharma Advanced Research Company Business Update

SPARC's partner Ocuvex received a US FDA Complete Response Letter for the PDP-716 drug application. The FDA cited manufacturing inspection findings but raised no other issues.

Source

NSE filing, NSE: SPARC. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Sun Pharma Advanced Research Company Ltd: key numbers

Share price
₹182.66
Market cap
₹5,928 Cr
Revenue (annual)
₹1,879 Cr
Net profit (annual)
₹1,553 Cr
P/E (TTM)
3.7×Sector 46.1×
Promoter holding
65.67%+0.00% QoQ
FII holding
3.74%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Sun Pharma Advanced Research Company Ltd

All →

Other business update announcements

All →